Evidence map›Paper›PMID 41744794›Full record

ReviewCells2026

The Role of CD4

Jijie Shao, Jintong Na, Honghua Huang, Lei Xiao, Fengqiu Dang, Rongshun Zheng, Liping Zhong, Yongxiang Zhao

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jijie ShaoThe First Clinical Medical College, Guangxi Medical University, Nanning 530021, China.
Jintong NaState Key Laboratory of Targeting Oncology, National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Major New Drugs Innovation and Development, Targeting Theranostics Research Center of Guangxi Higher Education, Guangxi Medical University, Nanning 530021, China.
Honghua HuangState Key Laboratory of Targeting Oncology, National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Major New Drugs Innovation and Development, Targeting Theranostics Research Center of Guangxi Higher Education, Guangxi Medical University, Nanning 530021, China.
Lei XiaoState Key Laboratory of Targeting Oncology, National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Major New Drugs Innovation and Development, Targeting Theranostics Research Center of Guangxi Higher Education, Guangxi Medical University, Nanning 530021, China.
Fengqiu DangState Key Laboratory of Targeting Oncology, National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Major New Drugs Innovation and Development, Targeting Theranostics Research Center of Guangxi Higher Education, Guangxi Medical University, Nanning 530021, China.
Rongshun ZhengState Key Laboratory of Targeting Oncology, National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Major New Drugs Innovation and Development, Targeting Theranostics Research Center of Guangxi Higher Education, Guangxi Medical University, Nanning 530021, China.
Liping ZhongState Key Laboratory of Targeting Oncology, National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Major New Drugs Innovation and Development, Targeting Theranostics Research Center of Guangxi Higher Education, Guangxi Medical University, Nanning 530021, China.ORCID 0000-0002-8624-3091
Yongxiang ZhaoThe First Clinical Medical College, Guangxi Medical University, Nanning 530021, China.

Funding

Guangxi Key Research and Development Program No. Guike AB23026058Guangxi Science and Technology Major Program No. AA24263028Scientific and Technological Innovation Major Base of Guangxi No.2022-36-Z05
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related mortality; its progression is strongly linked to the liver's immune microenvironment. T-helper (Th) cells, including Th1, Th2, Th17, and regulatory T cells (Tregs), play pivotal roles in modulating tumour immunity, either promoting or inhibiting tumour growth depending on their functional states and interactions within the tumour microenvironment. Imbalances in Th cell subsets, particularly between pro-inflammatory and immunosuppressive populations, have been associated with HCC progression and poor prognosis. Numerous studies have explored the therapeutic potential of restoring balance among Th cell subsets, focusing on modulating immune responses to improve HCC treatment outcomes. This paper reviews the differentiation and functional roles of Th cell subsets in HCC, exploring their contributions to tumour progression and immune suppression. Furthermore, this study discusses emerging immunotherapies aimed at modulating Th cell populations to improve clinical outcomes for HCC patients. Understanding the intricate roles of Th cells in the tumour microenvironment provides valuable insights for developing novel therapeutic strategies for liver cancer.

Indexed as

Carcinoma, HepatocellularImmunotherapyLiver NeoplasmsT-Lymphocytes, Helper-InducerAnimalsDisease ProgressionHumansT-Lymphocytes, RegulatoryTumor Microenvironmenthepatocellular carcinomaimmunotherapyregulatory T cellsT helper cellsTh/Treg balance

Identifiers

PMID41744794
PMCPMC12939046

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.